Stacey Kesterson
Women's Health · Morristown, TNNPI 1073594263
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AbbVie at 28.4% of the total. Reporting peaked in 2023 at $883 and has fallen 64.2% since, to $316 in 2025.
Across 126 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$586
- Mayne Pharma Commercial LLC$253
- Astellas Pharma US Inc$121
- Axsome Therapeutics, Inc.$87
- Exeltis, USA Inc.$86
- Avion Pharmaceuticals$83
- plus $850 from 24 others
What the payments were for
- Food & beverage$2,066100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,066 in reported general payments places this provider in the 80th percentile of 202 women's health providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PremarinEstrogens, Conjugated | 13 | $6,311 |
| GemtesaVibegron | 11 | $5,228 |
| Clobetasol Propionate | 38 | $2,402 |
| Estradiol | 78 | $1,927 |
| Estradiol (Twice Weekly)Estradiol | 20 | $1,586 |
| ValacyclovirValacyclovir Hcl | 11 | $540 |
| Medroxyprogesterone Acetate | 43 | $363 |
| Oxybutynin Chloride ErOxybutynin Chloride | 21 | $313 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 15 | $213 |
| Fluconazole | 34 | $198 |
| Metronidazole | 11 | $161 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 21 | $135 |
| Norethindrone | 13 | $117 |
| Amitriptyline Hcl | 16 | $47 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPremarin | $37 | $6,31113 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $24 | $5,22811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 202 women's health providers in Tennessee.
Other women's health in Morristown
- Haley WoodFranklin$92K
- Dana DemossNashville$76K
- Royanne MooreNashville$29K
- Laurie TompkinsBrentwood$27K
- Lana HirschNashville$24K
- Yoshie DarnallNashville$10K
- Lisa GoehringNashville$9K
- Anya ZerillaKnoxville$8K
- Catherine KingeryKnoxville$7K
- Lindsey BakshNashville$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.